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ABSTRACT 
KERATINOCYTES PRODUCE A PTH-SENSITIVE 
ADENYLATE CYCLASE-STIMULATING FACTOR 
John Jerome Merendino, Jr. 
1985 
Humoral hypercalcemia of malignancy (HHM) most frequently results 
from tumors of squamous epithelial origin. Studies suggest that the 
factor mediating HHM is distinct from PTH, but may act via the PTH 
receptor-coupled adenylate cyclase. This thesis addresses the 
hypothesis that non-malignant squamous epithelial cells produce a factor 
similar to that associated with HHM. 
Ten cultures of normal human keratinocytes, each derived from a 
different neonatal foreskin epidermis, were grown to confluence on 
irradiated murine 3T3 fibroblasts or collagen. Keratinocyte-conditioned 
medium (KCM) from these cultures was tested in the PTH-sensitive rat 
osteosarcoma (ROS 17/2.8) assay, which responds to stimulation with PTH 
receptor agonists by producing [3H]cAMP. KCM from each of the cultures 
demonstrated substantial adenylate cyclase-stimulating activity, 
generating from 4,400 to 31,280 cpm [3H]cAMP/assay well, with basal 
being 1,400. This is equivalent to the stimulation produced by 1 x 
10'10 to 8 x 10"10 M bovine parathyroid hormone (1-34) [bPTH-(1-34)]. 
Conditioned medium from four cultures of irradiated 3T3 cells and three 
cultures of dermal fibroblasts demonstrated no adenylate cyclase 
stimulation. Incubation with increasing concentrations of [Nle8,18, 
Tyr34]bPTH-(3-34)NH2, a competitive inhibitor of PTH, progressively and 
completely prevented the KCM-induced [3H]cAMP production. Incubation 
with a PTH antiserum inhibited the adenylate cyclase-stimulating 
activity of bPTH-(l-34), but not that of KCM. Concentrated KCM 
demonstrated dose-related production of cAMP in the PTH-sensitive renal 
cortical membrane adenylate cyclase assay. The active component of KCM 
is heat- and acid-stable, sensitive to trypsin and disulfide 
bond-reducing agents, and has a molecular weight of approximately 30,000 
daltons as estimated by gel filtration, far greater than that of native 
parathyroid hormone. 
These results indicate that keratinocytes produce a factor which is 
immunochemically and chromatographically distinct from PTH, but 
stimulates cAMP production via interaction with the PTH receptor. In 
every way tested thus far, the active component of KCM behaves 
identically to the adenylate cyclase-stimulating factor produced by 
tumors associated with HHM. This is the first report of such a factor 
to be obtained from non-neoplastic tissue. These studies suggest that 
HHM may result from the excessive secretion by tumors of a product 
produced by normal squamous epithelial cells. 
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INTRODUCTION 
Malignancy is the most common cause of hypercalcemia among 
hospitalized patients (1). Malignancy-associated hypercalcemia (MAHC) 
occurs in 10 to 20% of all cancer patients, and in up to 40% of patients 
with disseminated breast cancer, the neoplasm most often causing 
increased plasma Ca++ levels (2). Substantial evidence indicates that 
patients with MAHC fall into two groups based upon the pathophysiology 
of their increased extracellular Ca++ concentrations (3, 4). In the 
local osteolytic group, hypercalcemia results from direct destruction of 
bone by skeletal metastases. In the group having humoral hypercalcemia 
of malignancy (HHM), a blood-borne factor produced by tumor cells is 
thought to mediate bone resorption in the absence of skeletal 
metastases. 
Epidemiologic data reveals that most tumors of a given histologic 
type tend to cause hypercalcemia via the same pathophysiologic 
mechanism. For example, in the vast majority of hypercalcemic patients 
with breast cancer or multiple myeloma, the increased plasma Ca++ 
results from bone resorption by metastatic lesions (3, 5). Similarly, 
certain tumors are most often associated with HHM. In the first large 
series of patients with hypercalcemia in the absence of bone metastases, 
Lafferty (6) reported that nearly 60% of cases resulted from squamous 
cell carcinomas, particularly those of the lung, and hypernephromas. 
Other investigators noted a high incidence of non-metastatic MAHC in 
patients with squamous carcinomas of the head and neck (7, 8) and 
esophagus (7, 9, 10). Stewart et al. (3) found that in nearly 80% of 50 
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unselected patients with cancer and increased plasma Ca++ levels, the 
hypercalcemia was humorally mediated. Most of these patients had 
squamous cell, renal or bladder carcinomas. Indeed, every large series 
of patients with HHM has reported the majority to have tumors of 
squamous cell epithelial origin, including those of the head and neck, 
lung, esophagus, cervix, vulva or skin, as well as renal, bladder or 
ovarian carcinomas (11, 12, 13, 14, 15). 
Despite intense research, the humoral factor responsible for HHM 
remains unknown. As the prototypical bone-resorbing agent, PTH has long 
been regarded as a possible mediator. Indeed, patients with HHM share 
certain biochemical characteristics with those having primary 
hyperparathyroidism (1° HPT). First, some patients with hypercalcemia 
and malignancy demonstrate apparent parathyroid hyperplasia (16), though 
most authors feel this is due to a loss of glandular fat associated with 
cachexia (17). In addition, patients with HHM or 1° HPT both manifest 
hypophosphatemia as well as hypercalcemia. Parathyroid hormone is the 
only known substance to stimulate bone resorption and phosphorus 
excretion. This prompted Albright to propose that secretion of PTH by 
tumor tissue led to hypercalcemia in a patient with a renal carcinoma 
but only a single skeletal metastasis (18). In support of this notion, 
studies have revealed that patients with HHM or 1° HPT also demonstrate 
1)increased levels of nephrogenous cyclic 3', 5' adenosine monophosphate 
(cAMP), and 2)reduced renal tubular phosphorus thresholds (3). The term 
"pseudohyperparathyroidism", first used by Fry (19) in the description 
of a patient with non-metastatic MAHC, illustrates the previous 
pervasiveness of the conviction that ectopic PTH secretion causes HHM. 
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Several authors have demonstrated the presence of immunoreactive 
parathyroid hormone (iPTH) in extracts or histologic sections of some 
tumors from patients with HHM (20, 21, 22, 23, 24, 25, 26), or in the 
culture medium of cells obtained from such tumors (27, 28, 29). 
However, other workers have failed to demonstrate iPTH in such tumors 
(14). Further, even in those studies which did report iPTH in 
HHM-tumors, the amount of hormone was generally 30 to 1000 times lower 
than that obtained from parathyroid adenomas (17). A review of these 
studies suggests that the use of relatively non-specific assay systems 
accounts for the frequency with which iPTH has been detected in 
HHM-associated tumor tissue (30). 
Furthermore, despite the similarities between patients with HHM and 
1° HPT, these disease processes differ in important respects. For 
example, PTH increases bicarbonate excretion, so that patients with 1° 
HPT often demonstrate a hyperchloremic acidosis. However, patients with 
pseudohyperparathyroidism most often have a hypochloremic alkalosis (6, 
31). Additionally, recent work has shown that unlike patients with 1° 
HPT, those with HHM manifest l)markedly increased fractional Ca++ 
excretion, 2)decreased plasma levels of 1,25-dihydroxyvitamin D^, and 
3)low to undetectable plasma levels of iPTH (3, 32, 33, 34). Lastly, 
Simpson et. al. (35), using molecular biological techniques, demonstrated 
that non-parathyroid tumors causing humorally-mediated hypercalcemia do 
not contain messenger RNA coding for parathyroid hormone. Since most of 
the studies which have implicated PTH in the pathogenesis of HHM 
utilized older, less specific assay systems, there is currently little 
evidence to support ectopic secretion of this hormone as the mechanism 
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underlying the development of hypercalcemia in cancer patients without 
skeletal metastases. 
Various other substances have been implicated in the pathogenesis of 
HHM. For example, prostaglandin (PGE^) stimulates cAMP production in 
bone-derived cell culture (36) and bone resorption in fetal rat calvaria 
(37). Infusion of PGE2 into animals causes hypercalcemia (38). 
Tashjian and co-workers (39, 40) have shown that several animal tumors 
cause an HHM-like syndrome through the release of PGE2* These 
investigators have demonstrated that indomethacin and hydrocortisone, 
inhibitors of prostaglandin synthesis, can prevent PGE2 production by 
cultured tumor cells (41, 42) and correct hypercalcemia in tumor-bearing 
animals (43). Seyberth et al. (32) identified a group of patients with 
cancer, hypercalcemia and increased urinary levels of PGE-M, a PGE^ 
metabolite, whose serum Ca++ concentration fell in response to treatment 
with prostaglandin synthesis inhibitors. These results are somewhat 
difficult to interpret in light of the finding that such agents inhibit 
the bone-resorbing effect of PTH in vitro (44) and prevent hypercalcemia 
in rats given PTH infusions (45). While prostaglandins may mediate bone 
resorption in certain instances, recent series have failed to establish 
a role for these compounds in the pathogenesis of hypercalcemia in large 
numbers of patients with HHM (46). 
In addition to PTH and prostaglandins, vitamin D metabolites have 
been considered possible etiologic agents in HHM. Early reports 
suggested increased levels of certain vitamin D metabolites in patients 
with cancer and hypercalcemia (47), though subsequent studies 
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demonstrated no significant difference from control subjects (48). 
Still, macrophages are capable of la-hydroxylating 25-hydroxyvitamin 
to yield the maximally active hormone (49). Several authors have 
described patients with histiocytic lymphomas and hypercalcemia who 
displayed markedly increased plasma levels of 1,25-dihydroxyvitamin 
(30, 50). However, the vast majority of patients with HHM display 
strikingly low plasma 1,25-(OH)levels (3). Thus, while vitamin D 
or its metabolites may mediate cancer-associated hypercalcemia in rare 
instances, there is no evidence to suggest that this mechanism operates 
in a large proportion of patients with HHM. 
Currently, the two most active hypotheses hold that the substance 
underlying the development of HHM is either "growth factor-like" or 
"PTH-like". Epidermal growth factor (EGF) stimulates bone resorption in 
vitro either directly (51), or possibly by stimulating local production 
of PGE^ (52). Transforming growth factors (TGFs) are substances 
produced by many solid tumors which stimulate cell growth and 
replication, and confer properties of the transformed phenotype onto 
target cells (53). Transforming growth factors share many 
characteristics with EGF. Some bind directly to the EGF receptor, while 
others require the presence of EGF in order to promote the expression of 
transformed properties in target cells (54, 55, 56). Ibbotson et al. 
(57) described the presence of a bone-resorbing factor having the 
properties of a TGF in medium conditioned by cells derived from an 
HHM-associated tumor in rats. D'Souza and co-workers (58) determined 
the active component of such medium to have a molecular weight of 30,000 
daltons. This same group of investigators has recently presented 

evidence that EGF receptor antiserum, though not PTH receptor 
antagonists, inhibit bone resorption by such conditioned medium (59). 
Other investigators hold that while the bone-resorbing agent causing 
HHM differs from parathyroid hormone immunochemically, it may 
nonetheless share some functional characteristics with PTH. Indeed, a 
number of workers have demonstrated tumor-derived activity in various 
bioassays for parathyroid hormone. For example, Goltzman et al. (60) 
demonstrated that plasma from patients with HHM possessed increased PTH 
receptor-mediated glucose-6-phosphate dehydrogenase (G6PD) stimulating 
activity in an exquisitely sensitive cytochemical bioassay. Stewart £t 
al. (61) found that tumor extracts from four of five patients with HHM 
stimulated the PTH-sensitive renal cortical membrane adenylate cyclase 
assay, as well as the G6PD cytochemical bioassay. These authors also 
demonstrated that tumor-derived activity was competitively inhibited by 
PTH receptor antagonists, but unaffected by PTH antiserum. In contrast, 
tumors derived from normocalcemic cancer patients, or patients with 
local osteolytic MAHC, demonstrated little or no PTH-like activity. 
Likewise, Rodan and co-workers (62), using a clonally derived line of 
rat osteosarcoma (ROS 17/2.8) cells which contain a PTH-sensitive 
adenylate cyclase, tested conditioned media from cultures of 
non-hypercalcemic and HHM-associated tumor cells. They found that 
conditioned medium from HHM-causing tumor lines stimulated cAMP 
production by ROS cells, as well as bone resorption in vitro, while 
medium from the normocalcemic lines did not. This adenylate 
cyclase-stimulating activity, too, was competitively inhibitable with 
PTH receptor antagonists. Recently, Gkonos et al., (63) using a 
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dimethylbenzanthracene-induced squamous cell carcinoma model of HHM in 
mice, demonstrated the adenylate cyclase-stimulating factor to have a 
molecular weight of 20,000 to 30,000 daltons. 
Still other workers have exploited PTH-sensitive bioassays in 
molecular biological studies on cells from tumors causing HHM. Broadus 
et al. (64) injected polyadenylated RNA from HHM and control tumors into 
Xenopus oocytes, a method of preparing secretory translation products of 
mRNA derived from eukaryotic cells (65). Media from Xenopus oocytes 
injected with HHM-tumor mRNA stimulated the G6PD cytochemical bioassay 
in a competitively inhibitible fashion. Conditioned media from cultured 
oocytes injected with mRNA from control tumors demonstrated no 
cytochemical bioactivity. These studies all suggest that HHM-associated 
tumors produce a factor immunochemically distinct from PTH, but capable 
of stimulating cAMP formation and bone resorption via interaction with 
the PTH receptor. 
In sum, current evidence indicates that HHM may be mediated by a 
protein product of tumor cells having a molecular weight of 
approximatley 30,000 daltons, which interacts with the PTH 
receptor-coupled adenylate cyclase complex in several assay systems, and 
may share some properties with tumor-derived transforming growth 
factors. 
As stated previously, squamous epithelial carcinomas form the largest 
group of tumors causing HHM. This striking histologic uniformity raises 
the issue of whether normal squamous epithelial cells produce a factor 
similar to that secreted by their neoplastic counterparts. Under such 
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circumstances, HHM might result from the unregulated secretion by tumor 
cells of a normal cellular product. Until recently, studies of normal 
squamous epithelia were hampered by the inability to culture such cells 
readily. However, over the past several years methods for maintaining 
differentiating squamous epithelial cell cultures have been developed. 
The most widely studied such cells have been keratinocytes derived from 
human neonatal foreskin (66). This paper describes experiments in which 
conditioned medium from cultures of human neonatal keratinocytes was 
studied in the PTH-sensitive ROS and renal cortical membrane adenylate 
cyclase assays used in characterizing factors obtained from 
HHM-associated tumor tissue. The results indicate that cultured human 
keratinocytes produce a factor possessing physical and biological 
properties identical to those of the tumor cell product thought to 
mediate HHM. 
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METHODS 
Cell Culture. All cells were cultured at 37°C in a humidified 
atmosphere of 5% CC>2:95% air. Except where indicated, keratinocytes 
were grown on a "feeder layer" of murine fibroblasts. BALB/c 3T3 
fibroblasts CCL 92 (American Type Culture Collection, Rockville, MD) 
2 
were grown to confluence in 150 cm flasks in Dulbecco's modified 
Eagle's medium (DMEM; K.C. Biological, Lenexa, KA) supplemented with 10% 
bovine serum (Gibco Laboratories, Grand Island, NY), 100 U/ml penicillin 
and 100 yg/ml streptomycin. The cells were exposed to 1200 rads of 
X-radiation, incubated with 10 ml 2.5 g/L trypsin in Hank's balanced 
salt solution (trypsin in HBSS; Gibco) at 37°C for 5 minutes, and 
5 2 dispersed by pipetting. 6 x 10 cells were then plated into 28 cm 
dishes (Corning Glass Works, Corning, NY). Though unable to divide, 
these cells adhered to the culture flask and remained attached for 3-4 
weeks, providing a suitable surface for keratinocyte proliferation. 
Keratinocyte cultures were established according to the method of 
Rheinwald and Green (67), as modified by Milstone et al. (68). Human 
neonatal foreskins obtained at circumcision were placed in a complete 
medium (C-DMEM) consisting of DMEM with 20% fetal bovine serum (FBS; 
Gibco), 0.4 yg/ml hydrocortisone, 100 U/ml penicillin and 100 yg/ml 
streptomycin, and stored at 4°C until use, generally within 24 hours. 
Foreskins were washed twice with Ca++-Mg++ free phosphate buffered 
saline (CMF PBS; Gibco) containing penicillin and streptomycin. The 
subcutaneous fat and deep reticular layer of the dermis were then 
dissected away with iris scissors, and the tissue was incubated with 10 
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ml of 2.5 g/L trypsin in HBSS at 4°C overnight. The following day, the 
epidermis was removed as a single sheet, placed in 10 ml of C-DMEM, and 
dispersed into single cells by vigorous pipetting. 2 to 4 x 10^ cells 
in 5 ml C-DMEM were then plated into culture dishes containing 
irradiated 3T3 cells. One foreskin generally gave rise to 2-8 dishes on 
primary culture. Medium was changed two or three times per week. As 
the colonies of keratinocytes expanded, they displaced the 3T3 cells 
from the culture dish. The keratinocytes reached confluence in 
approximately 3 weeks, at which time they were subcultured by washing 
twice with CMF PBS and twice with 0.02% EDTA to remove residual 3T3 
cells, incubating with 50 mg/L trypsin-O.2% EDTA in HBSS (Gibco) at 37°C 
for 15 minutes, dispersing into single cells, pelleting, resuspending in 
C-DMEM, and replating onto a feeder layer of 3T3 cells. On first 
passage, cells were generally split in a ratio of 1:8 or 1:10, yielding 
2 
20-60 28 cm dishes per foreskin. 
As indicated in Results, for specificity studies two keratinocyte 
cultures were established directly on culture dishes coated with 
collagen. according to the method of Liu and Karasek (69). All 
procedures were carried out as described above, except that the cells 
were maintained in a different complete medium (C-MCDB), consisting of 
Ham's MCDB 153 medium (K.C. Biologicals) containing 10% FBS, 
hydrocortisone, penicillin and streptomycin. C-MCDB was used for those 
cultures lacking feeder 3T3 cells since it is designed for the optimal 
clonal growth of keratinocytes. However, this medium contains a lower 
Ca++ concentration than C-DMEM, thus preventing the stratification of 
cultured keratinocytes (70). 
10 

Once the first-passage cells reached confluence, samples of 
keratinocyte-conditioned medium (KCM) were collected at each medium 
change, or under the special conditions described in Results. Harvested 
KCM was centrifuged at 500g for 5 minutes to remove desquamated cells, 
the supernatant was decanted and either assayed immediately or stored at 
-70°C until use. 
Human fibroblasts were obtained from the dermis of neonatal foreskins 
following incubation with trypsin and separation of the epidermis. 
Dermal tissue was minced with iris scissors in 5 ml trypsin-HBSS and 
incubated at 37°C for 30 minutes. Repeated pipetting yielded single 
4 
cells which were pelleted, resuspended in C-DMEM, and plated at 2 x 10 
2 
cells/cm . Medium was changed as with the keratinocyte cultures. 
PTH-Sensitive Rat Osteosarcoma Cell Assay. Rat osteosarcoma (ROS) cells 
of the 17/2.8 strain, generously supplied by Dr. K. L. Insogna, were 
4 2 plated at 1 x 10 cells/cm into 16 mm culture wells on 24 well plates 
(Costar, Cambridge, MA), and grown in 0.5 ml of F-12 medium (Flow 
Laboratories, McLean, VA) containing 5% FBS, 100 U/ml penicillin and 100 
yg/ml streptomycin. Medium was changed every 3 days. The cells became 
confluent 10-12 days after plating, and, as described below, were used 
in a modified form of the PTH-sensitive adenylate cyclase assay 
described by Majeska et al. (71) on the sixteenth day. This assay 
measures the production of intracellular cAMP by ROS cells in response 
to stimulation with PTH. These cells also generate cAMP in response to 
isoproterenol, though this is mediated via a separate receptor mechanism 
(72). Isoproterenol was therefore used in various experiments to detect 
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inhibition of the assay system not resulting from a specific interaction 
with the PTH receptor or its agonists. 
The ROS assay was conducted at 37°C. Endogenous [^H]ATP production 
3 
was accomplished by incubating the cells with [ H]adenine (ICN 
Biomedicals, Irvine, CA) for 2 hours. The incubation medium was then 
aspirated, and the wells were washed twice with 0.5 ml Ca++-Mg++ free 
HBSS (Gibco). The cultures were then incubated with 0.1 ml/well F-12 
medium containing 2% FBS and 0.2 mM isobutylmethylxanthine (Sigma, St. 
Louis, MO), a phosphodiesterase inhibitor. Following this, 0.1 ml of 
the sample to be assayed was added. C-DMEM served as the control 
agonist; bovine parathyroid hormone (1-34) (bPTH-(1-34); Beckman 
Bioproducts, Palo Alto, CA) was the standard. Dilutions of bPTH-(l-34), 
KCM, isoproterenol or other materials to be tested were prepared in 
C-DMEM. Cells were then incubated for 5 minutes in the case of 
bPTH-(l-34), or 10 minutes when other agonist materials were added (see 
Results). Each assay was performed in duplicate. The reaction was 
terminated with 20 yl of 1.2 M trichloroacetic acid. One hundred 
microliters of a carrier solution containing 5 mM each of cAMP, adenine, 
adenosine, ADP and ATP, and 40 yl of a recovery standard containing 
32 
approximately 2000 cpm [ P]cAMP (ICN) were then added. The reaction 
mixture was transferred to plastic tubes containing 0.88 ml H^O, and 
frozen overnight at -20°C. The following day, samples were thawed, 
centrifuged at 3896 g in a Sorvall RC-5B refrigerated centrifuge 
(DuPont, Wilmington, DE) using an HS-4 rotor at 4500 rpm for 10 minutes. 
Supernatants were gently aspirated and neutralized with 4 N KOH in 
preparation for serial Dowex-alumina chromatography (see below). 
12 

PTH-Sensitive Renal Cortical Membrane Adenylate Cyclase Assay. 
Partially purified canine renal cortical membranes prepared by the 
method of Nissenson et al. (73) were kindly provided by Dr. A. F. 
Stewart. Each sample was assayed in duplicate. bPTH-(l-34) standards 
and KCM samples in volumes of 10 yl were added to 60 ]il of a reaction 
mixture containing 50 mM Tris-HCl, pH 7.4, 5.0 mM MgCl^, lOmM KCl, 1 mM 
EGTA, 1 mg/ml bovine serum albumin (BSA) , 0.125 mM ATP, 1.0 mM cAMP, 
0.11 U/ml creatine kinase, 5 mM creatine phosphate, 2.0 mM 
dithiothreitol, 10 yM 5'-guanylyl imidodiphosphate (all reagents from 
32 Sigma) 100,000 cpm [a- P]ATP (Amersham, Arlington Heights, IL), and 60 
yg renal cortical membrane protein. Reaction mixtures were incubated at 
30°C for 30 minutes. The reaction was terminated by adding 0.1 ml of a 
"stopping solution" containing 2.0 mM ATP, 0.5 mM cAMP and 10,000 cpm 
[^H]cAMP as a recovery standard, and heating to 100°C for 3 minutes. 
Reaction mixture volumes were then brought to 1.0 ml in preparation for 
serial chromatographic elution (61). 
3 32 Chromatographic Separation of cAMP from ATP. [ H]cAMP or [ PjcAMP, 
produced in the ROS or renal adenylate cyclase assays, respectively, was 
3 32 
separated from [ H]ATP, [a- P]ATP and other radiolabelled nucleotides 
by the method of Salomon et al. (74). Ion-exchange chromatography 
columns prepared with 2.8 ml of a 50% slurry of Dowex AG-50W-X4 (200-400 
mesh, hydrogen form; Bio-Rad Laboratories, Richmond, CA) were charged 
with 2 ml 1 N HC1 and washed with 20 ml H^O. Columns containing 600 mg 
Alumina WN-3 (Sigma) were washed with 10 ml 0.1 M immidazole-HCl, pH 7.4 
(Sigma). Samples from either the ROS assay or renal adenylate cyclase 
assay were decanted onto the Dowex columns, which were then washed twice 
13 

with 3.0 ml H^O. The first 3.0 ml eluate, containing primarily ATP, was 
discarded. The second eluate, containing the bulk of the cAMP, was 
passed over the alumina columns, to which the cyclic nucleotide adhered. 
An additional 1.0 ml H^O wash, which served to elute residual cAMP from 
the Dowex, was passed sequentially over both columns and saved in a 
liquid scintillation vial. To this was added 5 ml of 0.1 M immidazole 
used to elute cAMP from the alumina column. This aqueous sample was 
mixed with 15 ml Hydrofluor counting cocktail (National Diagnostics, 
32 Somerville, NJ). Tritium and P activities were then measured in a 
Minaxi Tri-Carb 4000 Series liquid scintillation counter (Packard 
Instrument Co., Downers Grove, IL), and corrected for recovery. 
Protease Sensitivity Experiments. 100 pi of 2.5 g/L trypsin in HESS was 
added to 1.0 ml samples of KCM, bPTH-(l-34) and isoproterenol prepared 
in C-DMEM. The samples were incubated at 27°C for 30 minutes, following 
which 20 yl of 25 g/L soybean trypsin inhibitor (Sigma) in 0.01M 
HAc-0.1% BSA was added. Samples were then incubated for an additional 
10 minutes, and placed on ice until the time of assay. 
8 18 34 Competitive Inhibition Studies. [Norleucine ' , Tyrosine ] bovine 
o i o 24 
PTH-(3-34) amide ([Nle ' , Tyr ]bPTH-(3-34)NH2; Bachem Fine Chemicals, 
Torrence, CA), a competitive inhibitor of PTH (75), was added to samples 
of bPTH-(l-34), KCM or isoproterenol in C-DMEM at the concentrations 
indicated in Results immediately prior to testing in the ROS assay. 
When assayed alone, the inhibitor was dissolved in C-DMEM. 
PTH Antiserum Studies. The PTH-immunoreactivity of KCM was examined in 
two distinct studies. The first measured iPTH using an exclusively 
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carboxy-terminal radioimmunoassay utilizing G-6, a goat anti-human PTH 
antiserum (76), generously provided by Dr. L. Mallette, Houston, TX, and 
the terminal 48 amino acid fragment of bovine PTH [bPTH-(37-84)] , 
125 
courtesy of Dr. R. MacGregor, Kansas City, MO, labelled with I, as 
the radioligand. 
The second study examined the effects of antiserum pre-incubation on 
the ability of PTH, KCM and isoproterenol to stimulate cAMP production 
in the ROS assay. G-5, a goat anti-human PTH antiserum reacting with 
both amino- and carboxy-terminal portions of the PTH molecule (77), also 
provided by Dr. Mallette, was mixed with test substances at a final 
dilution of 1:1000. Samples were incubated at 27°C for 1 hour 
immediately prior to assay. 
Gel Filtration Studies. A 5 ml sample of KCM was dialyzed against 4 L 
H^O at 4°C overnight using Spectra-Por 3 dialysis tubing (Spectrum 
Medical Industries, Los Angleles, CA). The sample was then lyophylized, 
resuspended in 350 -^1 of 0.1 M HAc, and centrifuged at 500g for 5 
minutes. Eighty microliters of the supernatant was saved for assay and 
protein determination; the remainder was subjected to gel filtration on 
Sephadex G-75 (Pharmacia, Piscataway, NJ) in a column with an effective 
3 
bed volume of 30 cm , using 0.1 M HAc as the buffer. Two milliliter 
fractions were collected. 250 yl of each fraction was lyophilized to 
remove HAc, resuspended in the same volume of C-DMEM, and tested in the 
ROS assay. 
Physical Characteristics. Samples of KCM were subjected to repeated 
freezing at -70°C and thawing at room temperature, snap-freezing in an 
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acetone-dry-ice bath, heating to 100°C for 10 minutes, lyophilization, 
500 mM acetic acid, or incubation with 0.065 M dithiothreitol (Sigma) at 
20°C for 20 hours prior to assay in the ROS system. 
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RESULTS 
ROS Assay. Figure 1 illustrates a representative standard curve of the 
production of cAMP by ROS 17/2.8 cells in response to increasing doses 
3 
of bPTH-(l-34). Accumulation of [ H]cAMP varies almost linearly with 
-11 -9 
the log of PTH concentration in the range of 5 x 10 to 10 M. Table 
1 shows the adenylate cyclase-stimulating activity of KCM from 10 
keratinocyte cultures, each obtained from a different foreskin, as well 
as that of conditioned medium from three cultures of dermal fibroblasts 
and 4 cultures of irradiated 3T3 cells. Eight of the keratinocyte 
cultures were grown on 3T3 cells in C-DMEM; the remaining 2 were grown 
on collagen in C-MCDB. The activity of each sample is given in terms of 
absolute [^H]cAMP production as well as the equivalent concentration of 
bPTH-(l-34), using the standard curve generated in each assay. 
One can readily see that each of the 10 samples of KCM possessed 
substantial adenylate cyclase-stimulating activity. For those 
3 
keratinocytes grown on 3T3 cells, the production of [ H]cAMP by KCM 
ranged from 8,170 to 31,280 cpm/well, with equivalent PTH concentrations 
being from 1.5 x 10 to 8.0 x 10 10 M. The adenylate 
cyclase-stimulating activity of KCM from keratinocytes grown on collagen 
3 
was somewhat lower, with [ H]cAMP production of 4,400 and 6,090 
cpm/well, corresponding to PTH concentrations of 1.0 x 10 ^ and 1.2 x 
10 10, respectively. This lower activity may have resulted from the 
fact that the lower Ca concentration of C-MCDB prevented these cells 
from stratifying (70). Cell numbers in these cultures were therefore 
several-fold lower, and the cells never underwent the differentiation 
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CONCENTRATION OF bPTH-(l-34), M 
Figure 1. Dose-response curve of bPTH-(l-34) in C-DMEM. Production of 
[3HJ cAMP varies almost linearly with log[bPTH-(1-34)] over the range of 
5 x lO'11 to 1 x 10'9 M. Basal (C-DMEM) in this assay was 430. 
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TABLE 1 
Adenylate Cyclase-Stimulating Activity 
of Conditioned Medium from Cultures of Keratinocytes, 
Irradiated 3T3 Cells, and Dermal Fibroblasts 
Medium Sample 
[3H]cAMP, 
cpm/well* 
Equivalent 
bPTH-(1-34) 
Cone., 10'11 
Keratinocytes on 
KCM 1 
3T3 Cells 
11,660 16 
KCM 2 8,170 16 
KCM 3 31,280 80 
KCM 4 12,600 19 
KCM 5 11,010 16 
KCM 6 10,520 15 
KCM 7 17,150 29 
KCM 8 9,400 15 
Keratinocytes on 
KCM 9 
Collagen 
6,090 12 
KCM 10 4,400 10 
3T3 Cells 
3T3 1 3,000 <5 
3T3 2 1,440 <5 
3T3 3 1,320 <5 
3T3 4 1,020 <5 
Dermal Fibroblasts 
DF 1 740 <5 
DF 2 2,350 <5 
DF 3 1,620 <5 
Basal 
C-DMEM 1,415 <5 
M# 
*[3H]cAMP cpm/well represent the mean of values obtained 
for each sample in all assays tested. 
^Equivalent bPTH-(l-34) concentration was obtained from 
a dose-response curve, such as that in Figure 1, gen¬ 
erated in each assay. If a sample was tested in more 
than one assay, the mean value is given. 
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associated with progressive keratinization and desquamation. 
Nonetheless, these results indicate that keratinocytes grown without 
feeder fibroblasts produce ROS cell adenylate cyclase stimulating 
activity. 
As stated previously, expanding colonies of keratinocytes displaced 
irradiated 3T3 cells from the surface of the culture dish. Confluent 
cultures, such as those from which KCM was obtained, were therefore 
largely devoid of feeder fibroblasts. However, since the cAMP-producing 
activity of those keratinocyte cultures grown on 3T3 fibroblasts was 
greater than that of cultures grown on collagen, conditioned medium from 
the murine cells themselves was studied for adenylate 
cyclase-stimulating capability. Several cultures of irradiated 3T3 
cells were maintained in C-DMEM in the absence of keratinocytes. Medium 
conditioned by these cells was tested in the ROS assay, and the results 
are shown in Table 1. Conditioned medium from these cultures 
demonstrated no significant increase in [^HjcAMP production above basal. 
3 
While one sample did generate 3000 cpm/well [ H]cAMP, in this particular 
assay the ROS cells responded to stimulation by PTH with greater than 
usual cAMP production. Therefore, this sample of 3T3 cell-conditioned 
medium possessed adenylate cyclase-stimulating activity lower than that 
of 5 x lO"11 M bPTH-(1-34). 
Keratinocyte cultures may become contaminated with dermal fibroblasts 
owing to the imperfect separation of epidermis from dermis in the 
primary explant. Any keratinocyte culture demonstrating contamination 
with fibroblasts on phase-contrast microscopy was discarded. As an 
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additional control, however, conditioned medium from three fibroblast 
cultures, each derived from a different foreskin dermis, was tested in 
the ROS assay. As with the irradiated 3T3 cells, conditioned medium 
3 
from these cultures demonstrated no significant increase in [ H]cAMP 
production above basal. Collectively, these studies strongly suggest 
that the adenylate cyclase-stimulating activity of KCM was produced by 
keratinocytes, rather than the other cell types which may have been 
present in the cultures. 
ROS Assay Incubation Time. Previous studies have demonstrated that 
various substances differ in the incubation time required to yield 
maximal [^HjcAMP production in the ROS assay (62). PTH yields an 
optimal response after 5 minutes; hence, incubations with PTH were 
terminated with TCA after 5 minutes. Isoproterenol increases cAMP 
production for 10 minutes, so that incubations with this agonist were 
terminated after this period of time. Media conditioned by 
HHM-associated tumor cells also yields maximal [^HjcAMP production at 10 
minutes. In order to determine the time required to optimize the 
response of ROS cells to KCM, samples were incubated for 5, 10 and 15 
minutes before the addition of TCA. Figure 2 demonstrates that [^H]cAMP 
accumulates rapidly during the first 5 minutes, peaks by the 10 minute 
mark, and falls by 15 minutes. Therefore, all samples of KCM tested in 
the ROS assay were incubated for 10 minutes prior to acidifying the 
reaction medium. 
Dose-Response Studies. In order to determine the response of the ROS 
system to varying concentrations of KCM, and to compare this behavior to 
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TIME, Minutes 
Figure 2. Time course of [3H]cAIIP production by ROS 17/2.8 cells in 
response to incubation with KCI1. Cells were incubated with 0.1 ml F-12 
medium containing 2% FBS and 0.2 mil isobutylmethylxanthine, as described 
in Methods. 0.1 ml of KCM was then added, and the cells were incubated 
for 5, 10 or 15 minutes further, following which 20 yl of 1.2 M TCA was 
added. As shown, the ROS cells demonstrated maximal [3H]cAMP production 
following incubation with KCM for 10 minutes. 
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that obtained with other agonists, serial 2-fold dilutions of KCM in 
C-DMEM were tested in the ROS assay. Figure 3 illustrates the results, 
along with dose-response curves for PTH and isoproterenol. The curves 
for KCM and PTH demonstrate nearly identical slopes over the range of 
cAMP production corresponding to the linear portion of the PTH standard 
curve. In contrast, the isoproterenol curve has a slope nearly twice as 
great as that of KCM or PTH, and cAMP production rises to at least twice 
that produced by maximal PTH stimulation. 
Time Course of Adenylate Cyclase-Stimulating Activity Appearance. In 
order to determine the time frame during which the adenylate 
cyclase-stimulating activity appeared in conditioned medium, samples of 
KCM taken from cultures at various times after medium change were tested 
in the ROS assay. The results of one such study are shown in Figure 4, 
upper curve. Samples were taken at 1, 2, 5, 10, 24, 48, 72 and 92 hours 
following medium change. The figure demonstrates that KCM had maximal 
cAMP-producing activity 48 hours after feeding. Repeat studies yielded 
virtually identical curves, indicating two days between medium changes 
to be optimal for collection of KCM. 
Effect of FBS Concentration on Production of Adenylate 
Cyclase-Stimulating Activity. The effect of varying concentrations of 
FBS on the cAMP-producing activity of KCM was studied in anticipation of 
concentrating the responsible factor. Maintaining confluent cultures in 
medium with concentrations of FBS as low as 1% resulted in activity 
production identical to that seen with higher serum concentrations (data 
not shown). Cultures could be maintained in such low-serum medium for 
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{3m J cAMF, 
cpm/well 
Figure 3. ROS assay dose-response curves for KCM (-•-), bPTH-(l-34) 
(-■-) and isoproterenol (-*-). Note that KCM and PTH yield 
nearly identical curves, while that of isoproterenol has a slope twice 
as great. 
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Figure 4. Time course of production of adenylate cyclase-stimulating 
activity by keratinocyte cultures. The upper curve (-•-) represents 
activity of KCM from a culture maintained in medium with 20% FBS 
(C-DMEM). The lower curve (-*-) represents activity of KCM from a 
culture maintained in serum-free medium. Basal in this assay was 430. 
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several feedings without significant loss of activity. However, cells 
washed with, and maintained in DMEM containing hydrocortisone, 
penicillin, and streptomycin, but lacking FBS, desquamated in large 
sheets after 2-3 medium changes. Further, even one such feeding with 
FBS-free DMEM resulted in a dramatic decrease in activity. Figure 4, 
lower curve, shows the time course of development of adenylate 
cyclase-stimulating activity by keratinocytes in the absence of FBS. 
Cells maintained in C-DMEM were washed three times and then fed with 
FBS-free DMEM, and the medium was sampled as before. The results differ 
from those obtained with C-DMEM in several respects. First, the maximal 
activity demonstrated by the serum-free KCM fell markedly below that 
which the same cells produced when fed with medium containing 20%, or 
even 1% serum. In addition, samples collected at 92 hours, rather than 
those taken at 48 hours, possessed the most activity. Finally, the 
activity of serum-free KCM shows an almost linear increase with time, 
rather than a rapid increase beginning soon after medium change. 
Protease Sensitivity. In the first step toward characterization of the 
adenylate cyclase-stimulating activity produced by keratinocytes, the 
effect of trypsin digestion on KCM was studied in the ROS system. 
Figure 5 demonstrates that incubation with 250 mg/L Trypsin at 27°C for 
30 minutes destroys virtually all of the cAMP-producing activity of both 
PTH and KCM, whereas trypsin incubation had relatively little effect on 
stimulation of adenylate cyclase by isoproterenol. The small inhibition 
of isoproterenol may have resulted from residual protease activity on 
the ROS cell membranes, despite the presence of trypsin inhibitor. 
Nonetheless, the assay system was still clearly capable of a vigorous 
26 

31,280 17,070 45,330 
% OniCIOAL 
ADEMYlATE 
CYCt.ASE- 
STItlULATIIIG 
ACTIVITY 
ABOVE BASAL 
TRYTSIH 
Fi.gu£e 5. Effect of trypsin incubation on adenylate cyclase-stimulating 
activity of KCM, 2.5 x 10-10 M bPTH-(l-34) and 5 x 10"6 II isoproterenol 
in C-DI1EII. Absolute [3H]cAHP cpm/well are given above the bars in each 
instance. 1.0 ml samples were mixed with 0.1 ml of 2.5 g/L trypsin in 
HESS and incubated at 27°C for 30 minutes. Following this, 20 j.il of 25 
g/L soybean trypsin inhibitor in 0.01 II HAc-0.1% BSA was added, the 
samples were incubated for an additional 10 minutes, and then placed on 
ice until the time of assay. Trypsin incubation completely eliminated 
the activity of KCII and PTH. The small inhibition of isoproterenol 
activity may have resulted from some residual protease activity on ROS 
cell membranes. The basal value in the assay for KCII and PTH was 2,340; 
for isoproterenol, basal was 950. 
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response in terms of cAMP production. These results indicate that the 
decreased activity seen following incubation of KCM with trypsin 
resulted from an effect of the protease on some constituent of the 
conditioned medium, strongly suggesting that the active factor in KCM is 
a protein or peptide susceptible to trypsin degradation. 
Competitive Inhibition Studies. In order to assess the mechanism of 
stimulation of adenylate cyclase by conditioned medium, KCM was 
8 18 
co-incubated with increasing concentrations of [Nle ' , 
34 
Tyr ]bPTH-(3-34)NH2 prior to assay in the ROS system. In vitro, this 
compound binds to the PTH receptor with nearly the avidity of the native 
hormone, in that its inhibitory constant (K^) virtually equals the 
affinity constant (K ) for PTH (75, 78). However, the analogue is 
devoid of agonist properties except at high concentrations (75, 79, 80). 
Previous studies have shown that this compound inhibits the 
cAMP-producing activity of PTH in the ROS system, while it has no effect 
on the stimulation of adenylate cyclase by isoproterenol (62). Figure 6 
illustrates the effect of increasing concentrations of this inhibitor on 
the production of [^H]cAMP in response to incubation with KCM. Note 
that over the range of concentrations shown, the production of cAMP 
falls by over 80%, and that from 10 to 10 M, the decline is 
essentially linear. The results of this experiment were borne out in 
six replications: in every instance cAMP production in response to KCM 
progressively declined with increasing concentrations of inhibitor, and 
in each case activity fell to or slightly below that of the inhibitor 
alone. This was true even of KCM having the highest potency: [^H]cAMP 
production in response to medium from culture 3 declined from 31,280 to 
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CONCENTRATION OF [Nle8,18, Tyr34]bPTH-(3-34)NH2, H 
Figure 6. Effect of co-incubation with increasing concentrations of 
jNle8,18, Tyr34]bPTH-(3-34)NH2 on the adenylate cyclase-stimulating 
activity of KCM. Activity of KCM plus inhibitor is shown by the curve; 
activity of inhibitor alone at 5 x 10-6 M is shown by the square. Note 
that the production of [3H]cAMP falls almost linearly with the log of 
inhibitor concentration over the range 1 x 10'7 to 1 x 10"6. In seven 
such experiments with various samples of KCM, ROS assay activity 
declined progressively to or below the stimulation produced by the 
competitive inhibitor alone. Basal in this assay was 850. 
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_ 5 
3,621 cpm/well, with inhibitor alone at 5 x 10 M yielding 5,360 
cpm/well. 
PTH Antiserum Studies. The first study characterizing the 
PTH-immunoreactivity of KCM examined the concentration of iPTH in 
samples of conditioned medium from cultures of keratinocytes, dermal 
fibroblasts, and irradiated 3T3 cells. There was no significant 
difference between samples in the three groups, with each sample 
125 yielding less than 5% displacement of [ I]bPTH-(37-84) on the standard 
curve. The maximum value obtained for any sample was 4 nlEq/ml, which 
-12 
corresponds to a bPTH-(l-34) concentration of less than 1 x 10 M, far 
below the limits of detectability of the ROS system. 
The second study tested the effect of pre-incubating KCM, bPTH-(l-34) 
and isoproterenol with G-5 PTH-antiserum prior to testing in the ROS 
assay. Stewart et al. (61) have previously demonstrated that increasing 
concentrations of this antiserum block the stimulation of the renal 
cortical membrane adenylate cyclase by parathyroid gland extract, but 
not by extracts of tumors from patients with HHM. Figure 7 illustrates 
-9 
the results obtained in the ROS system. Incubation of 1 x 10 M 
bPTH-(l-34) with a 1:1000 dilution of G-5 at 27°C for 1 hour resulted in 
3 
a fall of [ H] cAMP-forming activity of more than 60%. In contrast, 
incubating G-5 at a 1:1000 dilution with KCM or isoproterenol resulted 
in modest declines of 13% and 16%, respectively, probably representing 
non-specific interference with the assay system by the antiserum. These 
results demonstrated little variability across a range of PTH 
concentrations and KCM activities. For example, when incubated with the 
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Figure 7. Effect of pre-incubation with G-5 PTH antiserum on the 
adenylate cyclase-stimulating activity of KCM, 1 x 10"9 M bPTH-(l-34) 
and 5 x 10"6 M isoproterenol in C-DMEM. Absolute [3H]cAMP cpm/well are 
given above the bars in each instance. Samples were incubated with a 
1:1000 dilution of G-5 antiserum at 27°C for 1 hour prior to assay. 
Pre-incubation with antiserum resulted in a 63% decrease in the 
cAMP-forming activity of PTH, but had little effect on that of KCM or 
isoproterenol. Basal for KCM was 1,260; for PTH, 1790; and for 
isoproterenol, 950. 
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same concentration of antiserum used in the above experiment, the 
activity of 2.5 x 10 10 H bPTH-(l-34) declined from 9,450 to 4,120 
cpm/well, a fall of 65%, while the activity of KCM from culture 4 
declined from 9,400 to 8,050 cpm/well, a drop of only 17%. 
Gel Filtration and Physical Characteristics. Figure 8 shows the ROS 
cell adenylate cyclase-stimulating activity of fractions obtained from 
Sephadex G-75 gel filtration of concentrated KCM. As one can see, the 
cAMP-producing activity eluted in a discrete peak, with maximal activity 
in fraction 10 and substantial activities in fractions 9 and 11. This 
yields a preliminary estimate of approximately 30,000 for the molecular 
weight of the factor responsible for stimulation of adenylate cyclase in 
ROS cells. In contrast, native parathyroid hormone has a molecular 
weight of only 9,600. 
Studies of the physical properties of the cAMP-producing factor in 
KCM indicate that repeated freeze-thaw cycles, snap freezing, and 
heating to 100°C for 10 minutes all had no effect on activity. 
Likewise, lyophilization, and treatment with 500 mM HAc did not decrease 
the activity of KCM. However, treatment with the disulfide 
bond-reducing agent dithiothreitol resulted in loss of adenylate 
cyclase-stimulating activity. 
Renal Cortical Membrane Adenylate Cyclase-Stimulating Activity. 
Although the previous studies were all conducted in the ROS assay, this 
system is technically more cumbersome than the renal cortical membrane 
adenylate cyclase assay. However, the renal membrane assay is 
approximately 5- to 10-fold less sensitive to PTH than the ROS assay 
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FRACTION NUMBER 
Figure 8. Sephadex G-75 gel filtration of concentrated KCM. A 5 ml 
sample of KCM was dialyzed against 4 L H20 at 4°C overnight, 
lyophilized, and resuspended in 350 pi 0.1 M HAc. 270 pi of this 
solution was applied to a 30 cm3 Sephadex G-75 column using 0.1 II HAc as 
the buffer. Two milliliter fractions were collected, from which 250 pi 
aliquots were lyophylized, resuspended in the same volume of C-DMEM, and 
tested in the ROS assay. A single discrete peak of adenylate 
cyclase-stimulating activity eluted witli maximal activity in fraction 
10, corresponding to a molecular weight of approximately 30,000 daltons. 
Column markers with molecular weights and elution fraction of peak 
activity were as follows: ferritin, >450,000, fraction 6 (void volume); 
BSA, 68,000, fraction 8; a-chymotrypsinogen, 27,500, fraction 11; 
cytochrome c, 12,400, fraction 13; tetracycline, 444, fraction 19 (salt 
volume). 
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(81), with 1 x 10 10 M bPTH-(l-34) being the lower limit of 
detectability. Maximal stimulation in this system, approximately 4-fold 
"6 
above basal, results from stimulation with 1 x 10 M bPTH-(l-34). When 
tested in the renal cyclase assay in unconcentrated form, samples of KCM 
32 possessing the greatest ROS activity yielded [ P]cAMP production in the 
range of 400 cpm, only 1.5 times basal. Therefore, a sample of KCM was 
concentrated for use in renal adenylate cyclase assay. A 1.5 ml sample 
of KCM from a keratinocyte culture maintained in medium with 1% FBS was 
dialyzed against 4 L H^O at 4°C for 5 hours, lyophylized, and 
resuspended in 35 yl 10 mM HAc. This sample, and a three-fold dilution 
in 10 mM HAc, were assayed as described in Methods. These samples 
32 yielded [ P]cAMP production 2.28- and 1.70-fold above basal, 
respectively, corresponding to bPTH-(l-34) concentrations of 1.8 x 10 ^ 
and 7.6 x 10 ^ M. Although the responsiveness of the renal adenylate 
cyclase assay to KCM awaits further characterization, this preliminary 
result indicates that this system may be used in future study of the 
adenylate cyclase-stimulating factor produced by keratinocytes. 
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DISCUSSION 
These studies were undertaken in order to test the hypothesis that 
squamous epithelial cells produce a factor similar to that obtained from 
tumors associated with HHM. The results indicate that cultured human 
keratinocytes produce a substance possessing physical and biochemical 
properties identical to those of the adenylate cyclase-stimulating and 
bone-resorbing factor obtained from HHM-associated tumor tissue. 
Factors produced by keratinocytes and tumors causing HHM both 
1)stimulate cAMP formation in the ROS and renal cortical membrane assays 
(61, 62, 63); 2)stimulate the ROS assay optimally at 10 minutes (62); 
3)are sensitive to incubation with trypsin (63); 4)differ 
immunoreactively from PTH (61); 5)are acid- and heat-stable (58); and 
6)display an apparent molecular weight of approximately 30,000 daltons 
(58, 63). This is the first report of a factor having these 
characteristics to be obtained from non-neoplastic tissue. These 
studies raise the possibility that HHM may result from the unregulated 
secretion by tumor cells of a normal cellular product. Paraneoplastic 
syndromes frequently arise from the overzealous secretion by tumors of 
such factors (82). Indeed, some of the hormones whose regulation is now 
under study, such as ACTH and growth hormone, were first described as a 
result of the metabolic aberrancy caused by their excessive production 
in tumor tissue (83). 
Though the experimental results strongly support the above 
conclusions, they raise important issues requiring further study. 
Perhaps the most difficult data to interpret are those regarding the 
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origin of the adenylate cyclase-stimulating activity of KCM. 
Conditioned medium from all ten keratinocyte cultures tested displayed 
cAMP-producing activity significantly above basal, while medium from 
cultures of irradiated 3T3 cells and human dermal fibroblasts displayed 
no such activity. However, the activity of KCM from those cultures 
grown on collagen was lower that of medium from cells grown on 3T3 
fibroblasts. As indicated in Results, the different medium resulted in 
a smaller number of keratinocytes, and those that were present did not 
stratify. When grown under conditions promoting stratification, 
keratinocytes grown on collagen may demonstrate production of adenylate 
cyclase-stimulating activity as great as those grown on feeder 
fibroblasts. Further, even under these circumstances one would want to 
know the cell number and population dynamics in order to assess whether 
the process of keratinocyte differentiation affected activity (84). 
Finally, there is no evidence that decreased cell number or lack of 
differentiation alone accounts for the lower activity of these cultures. 
At present, one cannot exclude the possibility of an interaction between 
3T3 cells and keratinocytes promoting production of a cAMP-forming 
factor. 
While the experimental evidence indicates that neither 3T3 cells nor 
dermal fibroblasts generated the bioassay activity in KCM, other cell 
types, including melanocytes and Langerhans cells, reside within the 
epidermis, and thus may potentially contaminate keratinocyte cultures. 
Bringhurst et al. (85) describe a protease-sensitive bone-resorbing 
factor secreted by cultured tumor cells from a hypercalcemic patient 
with malignant melanoma. This raises the question of whether 
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melanocytes may have been the source of cAMP-producing activity in KCM. 
Selective culture of melanocytes requires conditions toxic to most other 
cell types (86), and these cells exist in very small numbers in 
keratinocyte cultures. More importantly, the factor produced by the 
melanoma line described above had an estimated molecular weight of 
12,500, and, unlike the active component of KCM, failed to stimulate the 
PTH-sensitive adenylate cyclase in renal cortical membranes (85). 
Langerhans cells must be considered a potential source of 
hypercalcemia-inducing factor because they are a specialized type of 
tissue macrophage. As stated in the Introduction, macrophages are 
capable of producing 1,25-(OH^-D^ (49), and patients with disorders of 
malignant macrophages (30, 50) or sarcoidosis (87) have hypercalcemia 
due to increased production of vitamin D. Vitamin D, however, 
stimulates neither the ROS nor renal cortical membrane assays, and 
shares none of the physical or chemical properties demonstrated by the 
active component of KCM. Furthermore, there exists no method for the 
selective culture of Langerhans cells, and, as with melanocytes, they 
constitute an extremely small proportion of the cells in keratinocyte 
cultures. These considerations argue strongly against either of these 
cell types as the source of adenylate cyclase-stimulating activity in 
KCM. 
One must also recognize the limitations of the present study in 
analyzing the nature of the active factor in KCM. The fact that the 
dilution curves for bPTH-(l-34) and KCM have nearly identical slopes, 
while that of isoproterenol is far steeper, entices the conclusion that 
parathyroid hormone and keratinocyte conditioned medium stimulate 
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adenylate cyclase via the same mechanism. While the inhibition by 
8 18 34 [Nle ' , Tyr ]bPTH- (3-34)NH2 indicates that the active factor in KCM 
interacts with the PTH receptor, one cannot say that it does so in a 
manner identical to that of PTH. First, the studies did not fully 
characterize the response of the ROS system to stimulation with KCM. 
Unconcentrated medium from the most active keratinocyte culture yielded 
cAMP production near the level of maximal stimulation by PTH. As 
demonstrated by the studies with isoproterenol, however, the ROS cells 
are capable of much greater cAMP formation. Therefore, one can draw no 
conclusion regarding the maximal stimulation which can be obtained from 
the active component of KCM, and cannot speculate about the shape of its 
dose-response curve at higher concentrations. Likewise, since there is 
no information regarding the concentration of adenylate 
cyclase-stimulating factor in KCM, one can know nothing of its potency 
relative to PTH. Furthermore, the production of cAMP in response to 
stimulation of the PTH receptor results from a complex series of 
biochemical interactions (88). In contrast to binding studies, the 
assay system used here yields no information about the affinity of the 
PTH receptor for the agonist component of KCM. 
Though the experimental evidence indicates a number of similarities 
between KCM- and HHM-derived adenylate cyclase-stimulating activities, 
one must take care in ascribing to the keratinocyte factor all the 
properties of the malignancy-associated bone-resorbing factor. Studies 
by Hermann-Erlee et al. (89) suggest that cAMP production and bone 
resorption may be mediated by PTH receptors with markedly differing 
affinities for the native hormone. Indeed, Rodan and Rodan (72) report 
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PTH receptor heterogeneity on ROS 17/2.8 cells, though binding to each 
type induced cAMP formation. These studies caution against attributing 
bone-resorbing activity to a factor merely on the basis of PTH receptor 
agonist activity in another system. 
On the other hand, such receptor heterogeneity may provide insight 
into the question of why HHM resembles 1° HPT in some respects but not 
others. Evidence from Strewler et al. (90) and others (91) indicates 
differing equivalent PTH potencies for the same preparation of 
HHM-factor in different assay systems. The ROS assay and fetal 
calvarial bone resorption assay appear to be 10- and 100-fold more 
sensitive to HHM-associated tumor extracts or conditioned medium than 
the renal cortical membrane assay relative to PTH. If HHM-causing 
tumors were to secrete a factor more potent in stimulating PTH-sensitive 
bone resorption and decreasing proximal tubular phosphorus reabsorption 
than in enhancing la-hydroxylation of 25-0^0^, a syndrome of 
hypercalcemia with reduced renal tubular phosphorus thresholds, 
increased nephrogenous cAMP and decreased plasma vitamin D levels might 
result. 
At present, there is no information regarding a possible 
physiological function for the cAMP-producing factor in keratinocyte 
conditioned medium. Interestingly, dermal fibroblasts possess a PTH 
receptor-coupled adenylate cyclase (79, 80). Although the role of this 
complex in vivo is unknown, and there is no information regarding 
stimulation of fibroblast adenylate cyclase by KCM, the presence of such 
receptors raises the possibility that a PTH receptor agonist serves a 
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regulatory function in human skin. One might postulate that the 
PTH-like factor produced by keratinocytes is the in vivo agonist of 
these receptors. Indeed, there are numerous examples of autocrine and 
paracrine factors affecting the growth and differentiation of dermal and 
epidermal cells (92). 
Alternatively, the keratinocyte-derived factor may have some systemic 
physiological function. Little is known of the part played by skin in 
Ca++ metabolism except that it is the source of photochemically 
generated cholecalciferol (93). However, various dermatological 
conditions other than squamous carcinoma of the skin are associated with 
derangements in Ca++ balance. For example, psoriasis vulgaris (94, 95), 
pustular psoriasis of von Zumbusch (96, 97, 98, 99), and impetigo 
herpetiformis (100, 101, 102) occur in the context of hypocalcemia. 
Most often, the low calcium results from decreased albumin levels (98, 
103, 104, 105, 106). However, in some instances decreases in ionized 
Ca++ have occurred as a result of hypoparathyroidism or malabsorption 
(94, 95, 97, 99, 102). In some such cases, treatment with vitamin D 
analogues or Ca++ infusions has been successful (107). These 
dermatological syndromes all involve keratinocyte hyperplasia. One 
might speculate whether the increased rate of keratinocyte proliferation 
generates larger quantities of adenylate cyclase-stimulating activity, 
leading to enhanced bone resorption with amelioration of the 
hypocalcemia. 
Definitive information regarding the nature of the factor responsible 
for the adenylate cyclase-stimulating activity produced by keratinocytes 
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must await purification in sufficient quantities to permit analysis of 
the structure by conventional chemical methods. The first step in 
producing such purified material would be to increase the specific 
activity of the protein in KCM by lowering the content of FBS. As 
indicated in Results, keratinocytes can be maintained for several 
feedings in low-serum medium without significantly decreased factor 
production. Although the total absence of FBS markedly lowered 
cAMP-producing activity, this was using media not supplemented with 
specific substances which enhance keratinocyte growth. Maciag and 
co-workers (108, 109) have developed a method for maintaining 
keratinocytes in a serum-free medium. If keratinocytes maintained in 
such a fashion were to demonstrate significant production of adenylate 
cyclase-stimulating activity, this would greatly facilitate purification 
of the responsible factor. Further studies are necessary in order to 
assess the feasibility of larger-scale factor production in low-serum or 
serum-free medium. 
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